Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 20th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Revenue	EBITDA	Earnings	EPS	Rev. Y/Y	Rev. 5Y	Earn. Y/Y	Earn. 5Y	Earnings Date
BMY	BRISTOL MYERS SQUIBB CO	$128.69B	$49.19B	$15.09B	$9.28B	$4.55	3.11%	2.08%	82.73%	N/A	2026-10-29
GILD	GILEAD SCIENCES INC	$194.91B	$30.46B	$1.80B	-$3.24B	-$2.60	5.52%	2.72%	N/A	N/A	2026-10-29
AMGN	AMGEN INC	$241.81B	$38.10B	$17.62B	$8.74B	$16.22	9.10%	8.37%	31.66%	10.38%	2026-11-03
ABBV	ABBVIE INC	$503.96B	$64.39B	$19.21B	$6.31B	$3.55	10.39%	3.69%	68.25%	-0.66%	2026-10-30
LLY	ELI LILLY & CO	$1.23T	$79.67B	$35.69B	$26.71B	$29.84	49.58%	24.41%	94.40%	34.90%	2026-10-29
MRK	MERCK & CO INC	$363.27B	$66.57B	$14.41B	$3.17B	$1.27	4.64%	8.68%	-80.46%	-10.41%	2026-10-29
PFE	PFIZER INC	$173.38B	$63.70B	$10.75B	$4.33B	$0.76	-0.21%	2.93%	-59.79%	-19.66%	2026-11-03
GRFS	GRIFOLS SA	$5.12B	$8.75B	$1.85B	$467.44M	$0.69	17.83%	6.33%	189.17%	-8.77%
NVS	NOVARTIS AG	$297.02B	$56.69B	$28.35B	$12.76B	$6.66	2.73%	1.92%	-3.48%	10.85%	2026-10-27
SNY	SANOFI	$102.33B	$55.59B	$14.33B	$4.50B	$1.87	3.31%	4.46%	-56.95%	-7.39%	2026-10-30
BIIB	BIOGEN INC	$37.51B	$10.03B	$1.86B	$834.60M	$5.68	0.31%	-3.03%	-45.80%	-14.92%	2026-10-28
GSK	GSK PLC	$102.60B	$44.27B	$12.33B	$6.43B	$3.20	2.17%	8.96%	38.94%	1.11%	2026-10-28
AZN	ASTRAZENECA PLC	$267.48B	$61.37B	$20.67B	$10.45B	$6.74	8.61%	15.75%	25.98%	18.54%	2026-10-30
JNJ	JOHNSON & JOHNSON	$644.22B	$99.34B	$26.81B	$16.10B	$6.68	7.80%	1.67%	-35.95%	-0.30%
AMRN	AMARIN CORP PLC	$245.02M	$186.23M	-$22.69M	-$27.12M	-$1.40	-15.10%	-21.39%	N/A	N/A	2026-10-28
SCLX	SCILEX HOLDING CO	$20.98M	$31.61M	-$425.16M	-$448.35M	-$49.70	-28.55%	16.49%	N/A	N/A	2026-11-13
MDCX	MEDICUS PHARMA LTD	$3.31M	$0.00	-$44.18M	-$56.66M	-$123.00	N/A	N/A	N/A	N/A	2026-11-13
NSRX	NASUS PHARMA LTD	$37.83M	$0.00	N/A	-$10.55M	-$1.09	N/A	N/A	N/A	N/A
MIRA	MIRA PHARMACEUTICALS INC	$26.43M	$0.00	-$10.78M	-$10.74M	-$0.11	N/A	N/A	N/A	N/A	2026-11-12
OGN	ORGANON & CO	$3.61B	$6.13B	$1.31B	$209.00M	$0.79	-2.45%	-0.64%	-70.85%	-35.12%	2026-11-09

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Oct 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 14 points higher than the general drug manufacturer industry average of 36.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 41.92% over the past year, overperforming other general drug manufacturer stocks by 7 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $65.25, an upside of 3.57% from Bristol Myers Squibb Co's current stock price of $63.00.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 46.15% have issued a Strong Buy rating, 0% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.

2. Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: A, Financials: C, and AI: C.

Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 24, which is -12 points lower than the general drug manufacturer industry average of 36. Although this number is below the industry average, our proven quant model rates GILD as a "B".

GILD passed 8 out of 38 due diligence checks and has weak fundamentals. Gilead Sciences has seen its stock return 29.42% over the past year, underperforming other general drug manufacturer stocks by -6 percentage points.

Gilead Sciences has an average 1 year price target of $156.91, a downside of -0.18% from Gilead Sciences's current stock price of $157.19.

Gilead Sciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Gilead Sciences, 63.64% have issued a Strong Buy rating, 9.09% have issued a Buy, 27.27% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Amgen (NASDAQ:AMGN) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Amgen (NASDAQ:AMGN) has a Due Diligence Score of 48, which is 12 points higher than the general drug manufacturer industry average of 36.

AMGN passed 17 out of 38 due diligence checks and has strong fundamentals. Amgen has seen its stock return 51.12% over the past year, overperforming other general drug manufacturer stocks by 16 percentage points.

Amgen has an average 1 year price target of $401.78, a downside of -10.17% from Amgen's current stock price of $447.28.

Amgen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 23 analysts covering Amgen, 21.74% have issued a Strong Buy rating, 13.04% have issued a Buy, 52.17% have issued a hold, while 13.04% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.65%, which is 3 percentage points higher than the general drug manufacturer industry average of 2.54%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 226.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.21%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.54%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 94.5% indicates that its high dividend yield might not be sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.54%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 55.2% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 2.39% in the last day, and up 3.72% over the last week. Biogen was the among the top gainers in the drug manufacturers - general industry, gaining 5.34% yesterday.

Biogen shares are trading higher after B of A Securities maintained its Neutral rating on the stock and raised its price target from $219 to $244.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 10 points higher than the general drug manufacturer industry average of 33. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 41.92% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 7 percentage points.

2. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 71, which is 38 points higher than the general drug manufacturer industry average of 33. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -21.99% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -57 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 57, which is 24 points higher than the general drug manufacturer industry average of 33. It passed 4 out of 7 valuation due diligence checks.

Biogen's stock has gained 71.84% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 36 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 1.78% over the next year.

5.88% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 17.65% of general drug manufacturer stocks are rated B (Buy), 64.71% are rated C (Hold), 5.88% are rated D (Sell), and 5.88% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 43.16x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Gilead Sciences (NASDAQ:GILD)

3. Amgen (NASDAQ:AMGN)

1. Pfizer (NYSE:PFE)

2. Sanofi (NASDAQ:SNY)

3. Bristol Myers Squibb Co (NYSE:BMY)

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Grifols Sa (NASDAQ:GRFS)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas